Oncovin

Indications for use of Oncovin include: Acute leukaemia Combination chemotherapy in: Hodgkins diseaseNon-Hodgkins malignant lymphomas RhabdomyosarcomaNeuroblastomaWilms tumourOsteogenic sarcomaMycosis fungoidesEwings sarcomaCarcinoma of the cervixBreast cancerMalignant melanomaLung cancer (Oat cell carcinoma)Children with neuroblastoma, osteogenic sarcoma, Ewings sarcoma, rhabdomyosarcoma, Wilms tumour, Hodgkins disease, non-Hodgkins lymphomas, embryonal carcinoma of the ovaries, and rhabdomyosarcoma of the uterus.Idiopathic thrombocytopaenic purpura resistant to other treatments (splenectomy and short-term treatment with adrenocortical steroids).NB: Oncovin is not the recommended first line treatment for idiopathic thrombocytopaenic purpura. Cancer chemotherapy usually involves the simultaneous use of several medications with different side effects and mechanisms of action. Oncovin is often chosen because it does not significantly suppress the bone marrow at recommended doses and its toxic effect is unique (at toxic doses Oncovin causes dysfunction of peripheral nerves to the hands and feet).

• Oncovin
• Vincristine sulfate injection

• Blenamax
• Blenoxane
• D.t.i.c
• Dacarbazine for injection
• Natulan
• Oncovin